<DOC>
	<DOCNO>NCT02778113</DOCNO>
	<brief_summary>The main purpose study evaluate safety tolerability LY900018 . The study drug deliver participant 's nostril ( intranasally ) give injection skin ( subcutaneously ) four study period . The study last 23 day participant .</brief_summary>
	<brief_title>A Study Glucagon Administered Different Forms Routes Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Body mass index ( BMI ) great equal 20.00 equal 28.00 kg/mÂ² . Light , non exsmokers . Have clinically significant disease capture medical history evidence clinically significant finding physical examination and/or clinical laboratory evaluation ( hematology , biochemistry , ECG urinalysis ) . Presence nose piercings . History significant hypersensitivity glucagon relate product ( include excipients formulation ) well severe hypersensitivity reaction ( like angioedema ) drug . Presence significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect . Presence significant cardiovascular , pulmonary , hematologic , neurological , psychiatric , endocrine , immunologic dermatologic disease . Presence clinically significant finding nasal examination bilateral anterior rhinoscopy . Fasting blood glucose 5.0 millimoles per liter ( mmol/L ) screening , follow 12hour fasting period . Fasting blood glucose assess glucose meter 5.5 mmol/L 0.5 hour dosing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>